Abstract
The Hyal-1 locus, which we have previously described and mapped to mouse chromosome 9, influences the serum levels and molecular weight forms of hyaluronidase. We have also shown that the growth of two transplantable tumors, the 3LL carcinoma and the B16F10 melanoma, is influenced by the alleles at Hyal-1, in that the tumors develop more slowly in congenic B6.C-Hyal-1a (also called HW23) mice than in the parental Hyal-1b C57BL/6 mice. Here we present evidence that tumor development is stimulated and mortality is accelerated in B6.C-Hyal-1a mice grafted with 3LL carcinoma cells when treated with alpha/beta interferon (IFN-alpha/beta) or with IFN-beta, whereas in IFN-treated C57BL/6 mice 3LL tumor growth is inhibited. Likewise, in B6.C-Hyal-1a mice grafted with B16F10 melanoma cells, IFN-alpha/beta treatment results in stimulation of tumor growth, whereas in IFN-treated C57BL/6 mice tumor growth, whereas in IFN-treated C57BL/6 mice tumor growth is inhibited and mortality delayed. Thus, IFN-alpha/beta treatment of B6.C-Hyal-1a mice results in stimulation of tumor development and sometimes in accelerated mortality. This is the opposite of the usually described effect of IFN treatment in mice, which is inhibition of tumor development and delayed mortality, as was indeed observed in the C57BL/6 mice in the present experiments. These results provide the first indication that host genes can up- or down-regulate the antitumor activity of IFN and that, on some genetic backgrounds, IFN treatment enhances rather than inhibits tumor development. This may help to explain the apparent discordance between mouse model studies, which hitherto have consistently reported inhibition of tumor formation by IFN, and the clinical trials, in which only a limited percentage of individuals show tumor regression while others have no beneficial effect or even have progression of disease in spite of the IFN treatment.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Colbère-Garapin F., Horodniceanu F., Kourilsky P., Garapin A. C. A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol. 1981 Jul 25;150(1):1–14. doi: 10.1016/0022-2836(81)90321-1. [DOI] [PubMed] [Google Scholar]
- De Maeyer-Guignard J., Cachard-Thomas A., De Maeyer E. Linkage analysis of the murine Hyal-1 locus on chromosome 9. J Exp Zool. 1991 May;258(2):246–248. doi: 10.1002/jez.1402580215. [DOI] [PubMed] [Google Scholar]
- De Maeyer-Guignard J., Cachard A., De Maeyer E. Isotopic labeling of mouse interferon by incorporation of radioactive amino acids during synthesis. Virology. 1982 Jul 30;120(2):472–477. doi: 10.1016/0042-6822(82)90047-2. [DOI] [PubMed] [Google Scholar]
- De Maeyer-Guignard J., De Maeyer E. Linkage analysis of the Gi alpha 2 gene on mouse chromosome 9. Mamm Genome. 1992;3(10):601–603. doi: 10.1007/BF00350628. [DOI] [PubMed] [Google Scholar]
- De Maeyer-Guignard J. Purification of mouse C-243 cell interferon by affinity chromatography and polyacrylamide gel electrophoresis. Methods Enzymol. 1981;78(Pt A):513–522. doi: 10.1016/0076-6879(81)78163-1. [DOI] [PubMed] [Google Scholar]
- De Maeyer E., De Maeyer-Guignard J. The growth rate of two transplantable murine tumors, 3LL lung carcinoma and B16F10 melanoma, is influenced by Hyal-1, a locus determining hyaluronidase levels and polymorphism. Int J Cancer. 1992 Jun 19;51(4):657–660. doi: 10.1002/ijc.2910510425. [DOI] [PubMed] [Google Scholar]
- Fidler I. J. Selection of successive tumour lines for metastasis. Nat New Biol. 1973 Apr 4;242(118):148–149. doi: 10.1038/newbio242148a0. [DOI] [PubMed] [Google Scholar]
- Fiszer-Szafarz B., De Maeyer E. Hyal-1, a locus determining serum hyaluronidase polymorphism, on chromosome 9 in mice. Somat Cell Mol Genet. 1989 Jan;15(1):79–83. doi: 10.1007/BF01534672. [DOI] [PubMed] [Google Scholar]
- Gresser I., Bourali-Maury C. Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastasis in mice. Nat New Biol. 1972 Mar 22;236(64):78–79. doi: 10.1038/newbio236078a0. [DOI] [PubMed] [Google Scholar]
- Gresser I. How does interferon inhibit tumor growth? Interferon. 1985;6:93–126. [PubMed] [Google Scholar]
- Higashi Y., Sokawa Y., Watanabe Y., Kawade Y., Ohno S., Takaoka C., Taniguchi T. Structure and expression of a cloned cDNA for mouse interferon-beta. J Biol Chem. 1983 Aug 10;258(15):9522–9529. [PubMed] [Google Scholar]
- Mann R., Mulligan R. C., Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell. 1983 May;33(1):153–159. doi: 10.1016/0092-8674(83)90344-6. [DOI] [PubMed] [Google Scholar]
- Markovic S. N., Murasko D. M. Neoadjuvant immunotherapy with interferon of the spontaneously metastasizing murine B16F10L melanoma. Int J Cancer. 1990 Apr 15;45(4):788–794. doi: 10.1002/ijc.2910450435. [DOI] [PubMed] [Google Scholar]
- Merigan T. C. Human interferon as a therapeutic agent: a decade passes. N Engl J Med. 1988 Jun 2;318(22):1458–1460. doi: 10.1056/NEJM198806023182208. [DOI] [PubMed] [Google Scholar]
- Nadeau J. H., Davisson M. T., Doolittle D. P., Grant P., Hillyard A. L., Kosowsky M. R., Roderick T. H. Comparative map for mice and humans. Mamm Genome. 1992;3(9):480–536. doi: 10.1007/BF00778825. [DOI] [PubMed] [Google Scholar]
- Ryd W., Hagmar B., Lundgren E., Strannegård O. Discrepant effects of interferon murine syngeneic ascites tumors and their solid metastasizing counterparts. Int J Cancer. 1979 Mar 15;23(3):397–401. doi: 10.1002/ijc.2910230319. [DOI] [PubMed] [Google Scholar]
- Sunkara P. S., Bowlin T. L., Rosenberger A. L., Fleischmann W. R., Jr Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice. J Biol Response Mod. 1989 Apr;8(2):170–179. [PubMed] [Google Scholar]